Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.09 -0.21 (-0.74%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer Unusual Options Activity
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
The September syndrome is already visible in U.S. stock markets. At this stage, investment in stocks with high dividend yield strong price appreciation potential in the short term should enhance... 
Via Talk Markets
Intel, Microsoft, Meta Platforms, Pfizer, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, major U.S. indices showed mixed results. The Dow Jones Industrial Average closed 0.5% higher at 41,622.08 
Via Benzinga
Topics Stocks
Exposures US Equities
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
Via Benzinga
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pfizer's sky-high dividend yield is tempting, but is it sustainable? 
Via The Motley Fool
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling. 
Via The Motley Fool
Topics Supply Chain
Exposures Supply Chain
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and... 
Via Benzinga
Exposures COVID-19
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr.... 
Via Newsfile
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
From Pfizer Inc.
Via Business Wire
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday. 
Via Investor's Business Daily
Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now
These stocks all trade at less than 14 times their expected future profits. 
Via The Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
These players have had their ups and downs -- but the future looks bright. 
Via The Motley Fool
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug. 
Via MarketBeat
Exposures Product Safety
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV... 
Via Benzinga
Is Hims & Hers Health the Next Teladoc?
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. 
Via The Motley Fool
Exposures COVID-19
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
From Pfizer Inc.
Via Business Wire
2 Beaten-Down Stocks That Could Be Great Buys on the Dip
They're down but not out, at least not yet. 
Via The Motley Fool
3 High-Yield Stocks to Buy Hand Over Fist in September
The time is right to buy all three of these high-yield dividend stocks. 
Via The Motley Fool
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu... 
Via Benzinga
Exposures COVID-19
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics,... 
Via Benzinga
3 No-Brainer Dividend Stocks With Yields Above 5% You Can Buy Now and Hold at Least a Decade
It's not hard to see how these well-seasoned businesses could deliver heaps of passive income to patient investors. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
These stocks pay great dividends and could be long-term winners. 
Via The Motley Fool
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.